ECCMID 2018

AWG Member Company Participation at ECCMID 2018

Thirteen AWG member companies presented data from their clinical and research programs at the annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) held April 21 – 24 in Madrid, Spain. Representatives from AWG member companies participated in 71 different oral sessions and poster presentations.

ECCMID is an annual scientific meeting that brings together the leading experts in the fields of clinical microbiology, infectious disease and infection control from across the globe to present and discuss the latest developments in the laboratory and in the clinic to advance research in a wide array of infectious diseases.

 

Saturday, April 21st

Oral Abstract Session: MDR Gram-negatives: Clinical and Epidemiological Challenges
Time: 8:45 – 10:45 a.m. CET
Location: Hall R

Melinta Therapeutics:
8:57 – 9:07 a.m. CET

Paper Poster Session: Influenza and other Respiratory Viruses
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena

Arsanis, Inc.:

Paper Poster Session: Aspergillus in the Laboratory
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena

Cidara Therapeutics:

SCYNEXIS, Inc.:

Paper Poster Session: Clinical trial experience – new antibacterial agents
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena

Melinta Therapeutics:

Motif Bio Plc:

Nabriva Therapeutics:

Paratek Pharmaceuticals:

Theravance Biopharma:

Paper Poster Session Activity of new or re-purposed non-beta-lactam drugs
against Gram-negatives
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena

Melinta Therapeutics:

Paratek Pharmaceuticals:

Paper Poster Session: Antibiotic toxicity: from mechanisms to clinical data
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena

Melinta Therapeutics:

Paper Poster Session: Pre-clinical PK/PD
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena

Nabriva Therapeutics:

Paper Poster Session: Clostridium difficile – clinical news
Time: 3:30 – 4:30 p.m. CET
Location: Paper Poster Arena

Nabriva Therapeutics:

Oral Abstract Session: New drugs and tricks against MDR bacteria
Time: 4:30 – 6:30 p.m. CET
Location: Hall L

Melinta Therapeutics:
4:54 – 5:04 p.m. CET

Spero Therapeutics:
5:06 p.m. – 5:16 p.m. CET

Sunday, April 22nd

Mini-Oral Flash Session: CMV – the challenge continues
Time: 11:30 a.m. – 12:30 p.m. CET
Location: Hall R
Melinta Therapeutics:
11:42 a.m. CET

Mini-Oral Flash Sessions: Snapshot on pre-registration clinical trials
Time: 11:30 a.m. – 12:30 pm. CET
Location: Hall Q

Motif Bio Plc:
11:50 a.m. CET

Paratek Pharmaceuticals:
11:54 a.m. CET

Paper Poster Session: The war of clones in Escherichia coli and Klebsiella
Time: 12:30 – 1:30 p.m. CET
Location: Paper Poster Arena

Arsanis, Inc.:

Paper Poster Session:  Focus: S. pneumoniae
Time: 12:30 – 1:30 p.m. CET
Location: Paper Poster Arena

Melinta Therapeutics:

Paper Poster Session: Community-acquired respiratory infections
Time: 12:30 – 1:30 p.m. CET
Location: Paper Poster Arena

Nabriva Therapeutics:

Paper Poster Session: Typing of bacterial pathogens – methods, results, applications
Time: 1:30 – 2:30 p.m. CET
Location: Paper Poster Arena

Arsanis, Inc.:

Paper Poster Session: Carbapenem plus carbapenemase inhibitor combinations: in
vitro and in vivo data
Time: 1:30 – 2:30 p.m. CET
Location: Paper Poster Arena

Melinta Therapeutics:

Paper Poster Session: Update on Pneumocystis
Time: 1:30 – 2:30 p.m. CET
Location: Paper Poster Arena

SCYNEXIS, Inc.

Oral Abstract Session: Drug combinations: pre-clinical evidence
Time: 4:00 – 6:00 p.m. CET
Location: Hall L

ContraFect Corporation:
5:46 p.m. – 5:56 p.m. CET

Mini-oral ePoster Sessions: Beta-lactamase inhibitors: from bench to bedside
Time: 4:00 – 5:00 p.m. CET
Location: ePoster Arena 3

Melinta Therapeutics:

Monday, April 23rd

Mini-oral ePoster Sessions: Urinary tract infections: optimal management in the era of
MDR
Time: 11:30 a.m.- 12:30 p.m. CET
Location: Paper Poster Arena

Iterum Therapeutics:
11:36 a.m. CET

Paper Poster Session: Microbial virulence and pathogenesis
Time: 12:30 – 1:30 p.m. CET
Location: ePoster Arena 1

Arsanis, Inc.:

Paper Poster Session: Biofilms I – Gram-positive pathogens
Time: 12:30 – 1:30 p.m. CET
Location: Paper Poster Arena

ContraFect Corporation:

Paper Poster Session: Resistance in various Gram-positives
Time: 1:30 – 2:30 p.m. CET
Location: Paper Poster Arena

Motif Bio Plc:

Nabriva Therapeutics:

Paratek Pharmaceuticals:

Theravance Biopharma:

Paper Poster Session: Exploring antibacterial activity with the help of
pharmacology
Time: 12:30 – 1:30 p.m. CET
Location: Paper Poster Arena

Iterum Therapeutics:

Paper Poster Session: Seeking synergy in drug combinations
Time: 1:30 – 2:30 p.m. CET
Location: Paper Poster Arena

Spero Therapeutics:

Mini-oral ePoster Session: Hot topics in antifungal use
Time: 2:30 – 3:30 p.m. CET
Location: ePoster Arena 1

Amplyx Pharmaceuticals:
2:54 p.m. CET

3:00 p.m. CET

Tuesday, April 24th

Oral Abstract Session: News in Antifungal Therapy
Time: 9:00-11:00 a.m. CET
Location: Hall K

Cidara Therapeutics:
9:22 – 9:32 a.m. CET

9:34 – 9:44 a.m. CET

10:10 – 10:20 a.m. CET

10:34 – 10:44 a.m. CET

Amplyx Pharmaceuticals:
9:58 – 10:08 a.m. CET

10:43 – 10:53 a.m. CET

Paper Poster Session: Phages and therapeutic antibodies
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Arena

ContraFect Corporation:

Paper Poster Session: Clinical pharmacokinetics
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Arena

Melinta Therapeutics:

Spero Therapeutics:

Paper Poster Session: Skin and soft-tissue infections: risk factors and management
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Arena

Melinta Therapeutics:

Paper Poster Session: Urinary tract infection – risks, diagnosis, treatment
Time: 12:30 p.m. – 1:30 p.m. CET
Location: Paper Poster Arena

Iterum Therapeutics:

Oral Abstract Session: Innovations in molecular pathogen detection
Time: 1:30 – 3:30 p.m. CET
Location: Hall C

T2 Biosystems:
2:42 p.m. CET

ePoster Viewing
Satuday, April 21st  – Tuesday, April 24th
Time: 8:00 a.m. – 6:00 p.m. CET

Various bacterial infections:

Melinta Therapeutics:

Motif Bio Plc: